Janet B Mcgill

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5376698/publications.pdf

Version: 2024-02-01

279798 182427 3,404 54 23 51 citations h-index g-index papers 54 54 54 3558 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections. JAMA - Journal of the American Medical Association, 2017, 317, 371.	7.4	834
2	Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections. Annals of Internal Medicine, 2017, 167, 365.	3.9	385
3	Continuous Subcutaneous Insulin Infusion and Multiple Daily Injection Therapy Are Equally Effective in Type 2 Diabetes: A randomized, parallel-group, 24-week study. Diabetes Care, 2003, 26, 2598-2603.	8.6	235
4	Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. New England Journal of Medicine, 2020, 382, 2493-2503.	27.0	228
5	Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes. JAMA - Journal of the American Medical Association, 2020, 323, 2397.	7.4	191
6	Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin. JAMA - Journal of the American Medical Association, 2021, 325, 2262.	7.4	182
7	Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment. Diabetes Care, 2013, 36, 237-244.	8.6	162
8	Circulating 1,5-Anhydroglucitol Levels in Adult Patients With Diabetes Reflect Longitudinal Changes of Glycemia: A U.S. trial of the GlycoMark assay. Diabetes Care, 2004, 27, 1859-1865.	8.6	126
9	Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 700-708.	11.4	99
10	Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Diabetes, Obesity and Metabolism, 2019, 21, 1199-1208.	4.4	83
11	Anemia and the role of erythropoietin in diabetes. Journal of Diabetes and Its Complications, 2006, 20, 262-272.	2.3	69
12	Safety of Sodium-Glucose Co-Transporter 2 Inhibitors. American Journal of Cardiology, 2019, 124, S45-S52.	1.6	62
13	Design of the COmbinatioN effect of Finerenone and EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE). Nephrology Dialysis Transplantation, 2023, 38, 894-903.	0.7	48
14	Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension. Clinical Cardiology, 2001, 24, 66-72.	1.8	46
15	Clinical safety of the selective PKC-β inhibitor, ruboxistaurin. Expert Opinion on Drug Safety, 2006, 5, 835-845.	2.4	42
16	The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review. Diabetes Therapy, 2014, 5, 43-63.	2.5	40
17	Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol—Rationale, Design, and Baseline Data. Diabetes Care, 2019, 42, 1454-1463.	8.6	39
18	Potentiation of abnormalities in myocardial metabolism with the development of diabetes in women with obesity and insulin resistance. Journal of Nuclear Cardiology, 2011, 18, 421-429.	2.1	38

#	Article	IF	CITATIONS
19	Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia. BMJ Open Diabetes Research and Care, 2014, 2, e000011.	2.8	31
20	Type 2 diabetes, obesity, and sex difference affect the fate of glucose in the human heart. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 308, H1510-H1516.	3.2	31
21	Inhaled Technosphere Insulin Versus Inhaled Technosphere Placebo in Insulin-Naìve Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetes Agents. Diabetes Care, 2015, 38, 2274-2281.	8.6	30
22	Culinary Medicine: Advancing a Framework for Healthier Eating to Improve Chronic Disease Management and Prevention. Clinical Therapeutics, 2019, 41, 2184-2198.	2.5	30
23	High prevalence of comorbid autoimmune diseases in adults with type 1 diabetes from the HealthFacts database. Journal of Diabetes, 2019, 11 , 273-279.	1.8	29
24	What's Wrong with This Picture? A Critical Review of Current Centers for Medicare & Dedicare & Services Coverage Criteria for Continuous Glucose Monitoring. Diabetes Technology and Therapeutics, 2021, 23, 652-660.	4.4	26
25	The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin. Diabetes Care, 2021, 44, 2729-2737.	8.6	24
26	Progress and Controversies: Treating Obesity and Insulin Resistance in the Context of Hypertension. Journal of Clinical Hypertension, 2009, 11, 36-41.	2.0	22
27	Real-World Evidence Supporting Tandem Control-IQ Hybrid Closed-Loop Success in the Medicare and Medicaid Type 1 and Type 2 Diabetes Populations. Diabetes Technology and Therapeutics, 2022, 24, 814-823.	4.4	22
28	Relationship Between Skin Intrinsic Fluorescence—an Indicator of Advanced Glycation End Products—and Upper Extremity Impairments in Individuals With Diabetes Mellitus. Physical Therapy, 2015, 95, 1111-1119.	2.4	19
29	Pharmacotherapy in Type 2 Diabetes: A Functional Schema for Drug Classification. Current Diabetes Reviews, 2012, 8, 257-267.	1.3	18
30	Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases, 2019, 73, 309-315.	1.9	18
31	Monogenic and syndromic diabetes due to endoplasmic reticulum stress. Journal of Diabetes and Its Complications, 2021, 35, 107618.	2.3	18
32	Optimizing Postprandial Glucose Management in Adults With Insulin-Requiring Diabetes: Report and Recommendations. Journal of the Endocrine Society, 2019, 3, 1942-1957.	0.2	16
33	Impact of Incretin Therapy on Islet Dysfunction: An Underlying Defect in the Pathophysiology of Type 2 Diabetes. Postgraduate Medicine, 2009, 121, 46-58.	2.0	15
34	ESRD After Heart Failure, Myocardial Infarction, or Stroke in TypeÂ2 Diabetic Patients With CKD. American Journal of Kidney Diseases, 2017, 70, 522-531.	1.9	15
35	Low dose chloroquine decreases insulin resistance in human metabolic syndrome but does not reduce carotid intima-media thickness. Diabetology and Metabolic Syndrome, 2019, 11, 61.	2.7	15
36	Visual Field Loss in Patients With Diabetes in the Absence of Clinically-Detectable Vascular Retinopathy in a Nationally Representative Survey., 2019, 60, 4711.		14

#	Article	IF	CITATIONS
37	Strategies for glucose control in a study population with diabetes, renal disease and anemia (Treat) Tj ETQq1	. 0.784314 2.8	rgBT ₁₃ /Overlo
38	Effect of a Shoulder Movement Intervention on Joint Mobility, Pain, and Disability in People With Diabetes: A Randomized Controlled Trial. Physical Therapy, 2018, 98, 745-753.	2.4	11
39	Safety of Sodium-Glucose Co-Transporter 2 Inhibitors. American Journal of Medicine, 2019, 132, S49-S57.e5.	1.5	11
40	Moyamoya syndrome causing stroke in young women with type 1 diabetes. Journal of Diabetes and Its Complications, 2016, 30, 1640-1642.	2.3	10
41	Diabetic Kidney Disease. Missouri Medicine, 2016, 113, 390-394.	0.3	9
42	Understanding inhaled Technosphere Insulin: Results of an early randomized trial in type 1 diabetes mellitus. Journal of Diabetes, 2021, 13, 164-172.	1.8	8
43	Comprehensive Pulmonary Safety Review of Inhaled Technosphere® Insulin in Patients with Diabetes Mellitus. Clinical Drug Investigation, 2020, 40, 973-983.	2.2	7
44	Lost in Translation: A Disconnect Between the Science and Medicare Coverage Criteria for Continuous Subcutaneous Insulin Infusion. Diabetes Technology and Therapeutics, 2021, 23, 715-725.	4.4	7
45	Update on Biosimilar Insulins: A US Perspective. BioDrugs, 2020, 34, 505-512.	4.6	6
46	Evidenceâ€based treatment of hyperglycaemia with incretin therapies in patients with type 2 diabetes and advanced chronic kidney disease. Diabetes, Obesity and Metabolism, 2020, 22, 1014-1023.	4.4	5
47	High prevalence of systemic rheumatic diseases in women with type 1 diabetes. Journal of Diabetes and Its Complications, 2018, 32, 737-739.	2.3	4
48	Biologic and social factors predict incident kidney disease in type 1 diabetes: Results from the T1D exchange clinic network. Journal of Diabetes and Its Complications, 2019, 33, 107400.	2.3	4
49	Anti-Diabetes Therapy: Safety Considerations for Patients With Impaired Kidney Function. Postgraduate Medicine, 2014, 126, 161-171.	2.0	2
50	Mistaken Identity: Missed Diagnosis of Type 1 Diabetes in an Older Adult. Medical Research Archives, 2019, 7, .	0.2	2
51	Insulin Receptor Autoantibody–mediated Hypoglycemia in a Woman With Mixed Connective Tissue Disease. Journal of the Endocrine Society, 2022, 6, bvab182.	0.2	2
52	Selecting among ADA/EASD tier 1 and tier 2 treatment options. Journal of Family Practice, 2009, 58, S26-34.	0.2	1
53	Safety and Efficacy of Hyperglycemia Urgency Order Set. Journal of Diabetes Science and Technology, 2014, 8, 1062-1063.	2.2	0
54	Letter to the Editor from McKee and McGill: "Glycemic Control and Variability of Diabetes Secondary to Total Pancreatectomy Assessed by Continuous Glucose Monitoring― Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4298-e4299.	3.6	0